Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

Abstract: The present disclosure is directed to protocells or nanoparticles, which are optionally coated with a lipid bilayer, which can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and/or diagnosis of bone cancer, often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate cancer, breast cancer, lung cancer and ovarian cancer, among numerous others. These protocells or nanoparticles target bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and/or diagnostic agents for purposes of treating, diagnosing and/or monitoring the therapy of the bone cancer. Osteotropic protocells or nanoparticles, pharmaceutical compositions comprising a population of osteotropic protocells or nanoparticles and methods of diagnosing, treating and/or monitoring therapy of bone cancer are representative aspects.

Abstract: In one embodiment, a sample probe has a cap and a base, wherein the cap includes a grip portion and a projection portion. The projection portion fits within a hollow portion of a filter such that the filter is disposed on the outside of the projection portion and the filter and the cap form a cap assemblage. The base comprises a base recess that receives a portion of the cap assemblage including the filter. The cap and base include corresponding media transfer regions adjacent and connected to the filter that reduces flow resistance and chances of blockage and/or contamination during dissolution-testing sampling using the sample probe.

Abstract: In one aspect, the disclosure provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit cell binding specificity. For example, MSNPs and protocells of the disclosure may be used to target specific delivery of therapeutic agents to CD19 or EGFR expressing cancer cells, or target specific delivery of therapeutic agents to other cell types. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract: A method to prepare a population of metal-organic polyhedra (MOP) supported micelle nanoparticles (NPs), and a composition comprising MOP supported micelle NPs, are provided.

Abstract: A membrane structure for moving a gaseous object species from a first region having an object species first concentration, through the membrane structure, to a second region having an object species second concentration different from the first concentration is described. The membrane includes a supporting substrate having a plurality of pores therethrough, each of the plurality of pores defined by a first end, a second end and a surface of the supporting substrate extending between the first end and the second end as well as a nanoporous layer within the plurality of pores, wherein the nanoporous layer comprises a hydrophilic layer and a hydrophobic layer. The membrane also includes a liquid transport medium within the hydrophilic layer. The liquid transport medium includes a liquideous permeation medium and at least one enzyme within the liquideous permeation medium. The at least one enzyme is reinforced by at least one stabilizing component.

Abstract: An encapsulated living (viable) mammalian cell, and methods of making and using that cell, are provided.

Abstract: A modified vertebrate cell comprising a vertebrate cell encased in reversibly interlinked metal-organic framework (MOF) nanoparticles, and methods of making and using the modified cell, are provided.

Abstract: A membrane structure for moving a gaseous object species from a first region having an object species first concentration, through the membrane structure, to a second region having an object species second concentration different from the first concentration is described. The membrane includes a supporting substrate having a plurality of pores therethrough, each of the plurality of pores defined by a first end, a second end and a surface of the supporting substrate extending between the first end and the second end as well as a nanoporous layer within the plurality of pores, wherein the nanoporous layer comprises a hydrophilic layer and a hydrophobic layer. The membrane also includes a liquid transport medium within the hydrophilic layer. The liquid transport medium includes a liquideous permeation medium and at least one enzyme within the liquideous permeation medium. The at least one enzyme is reinforced by at least one stabilizing component.

Abstract: Zr-based MOF NPs for cryopreservation of cells including, for example, red blood cells.

Abstract: The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein.

Abstract: Methods of preparing red blood cell mimetics and functionalized red blood cell mimetics, and methods of making and using those mimetics, are provided.

Abstract: The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein.

Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.

Abstract: Methods and apparatus for long read, label-free, optical nanopore long chain molecule sequencing. In general, the present disclosure describes a novel sequencing technology based on the integration of nanochannels to deliver single long-chain molecules with widely spaced (>wavelength), ˜1-nm aperture “tortuous” nanopores that slow translocation sufficiently to provide massively parallel, single base resolution using optical techniques. A novel, directed self-assembly nanofabrication scheme using simple colloidal nanoparticles is used to form the nanopore arrays atop nanochannels that unfold the long chain molecules. At the surface of the nanoparticle array, strongly localized electromagnetic fields in engineered plasmonic/polaritonic structures allow for single base resolution using optical techniques.

Abstract: The present disclosure is directed to methods of producing monosized protocells from monosized mesoporous silica nanoparticles (mMSNPs) and their use for targeted drug delivery formulations and systems and for biomedical applications. The present disclosure is also directed in part to a multilamellar or unilamellar protocell vaccine to deliver full length viral protein and/or plasmid encoded viral protein to antigen presenting cells (APCs) in order to induce an immunogenic response to a virus.

Abstract: The present disclosure is directed to methods of producing star-like mesoporous silica nanoparticles (SMSNPs) and protocells SMSNPs and their use for targeted drug delivery formulations and systems and for biomedical applications. Also provided are methods of producing monosized protocells from monodisperse SMSNPs and their use for targeted drug delivery formulations and systems and for biomedical applications.

Abstract: The present disclosure is directed to methods of producing lipid coated nanoparticles useful for biomedical applications, e.g., vaccines, adjuvants. The present disclosure is also directed in part to, e.g., multilamellar or unilamellar, protocell vaccines.

Abstract: Provided are polymer-aerogel composite coatings, devices and articles including polymer-aerogel composite coatings, and methods for preparing the polymer-aerogel composite. The exemplary article can include a surface, wherein the surface includes at least one region and a polymer-aerogel composite coating disposed over the at least one region, wherein the polymer-aerogel composite coating has a water contact angle of at least about 140° and a contact angle hysteresis of less than about 1°. The polymer-aerogel composite coating can include a polymer and an ultra high water content catalyzed polysilicate aerogel, the polysilicate aerogel including a three dimensional network of silica particles having surface functional groups derivatized with a silylating agent and a plurality of pores.